Agilent (A) Q2 2026 earnings review
Margin Expansion and Equipment Rebound Overshadow Cash Flow Weakness
Agilent delivered a strong Q2, beating expectations and raising FY26 guidance. A Reversing trend in the Applied Markets Group (AMG) and Accelerating demand in Life Sciences (LDG) drove a 6.3% core revenue growth. The 'Ignite' operating system continues to generate structural leverage, pushing Non-GAAP operating margins up 130 bps to 26.4%. However, the quality of these results is marred by two major red flags: a sharp deceleration in the highly profitable, recurring CrossLab (ACG) segment, and Operating Cash Flow moving opposite to Net Income due to a significant inventory build.
🐂 Bull Case
The 11% core growth in AMG and 9% in LDG confirms that customers are aggressively upgrading aging instrument fleets, completely Reversing the capex caution seen in 2024.
The Ignite transformation is delivering structural profitability. Expanding operating margins by 130 bps while launching new platforms proves the company can invest for growth without sacrificing the bottom line.
🐻 Bear Case
The recurring service and consumables business (ACG) dropped to 2% core growth, significantly lagging the company average. If service attach rates are failing, long-term margin stability is at risk.
Operating cash flow declined YoY despite a 21% surge in GAAP Net Income. An $85M cash drain from inventory suggests production is outstripping real-time demand.
⚖️ Verdict: 🟢
Bullish. The return of robust instrument sales and excellent margin execution outweigh near-term cash flow and segment mix concerns, justifying the raised full-year guidance.
Key Themes
Applied Markets (AMG) Reversing to High Growth
AMG flipped from being a sluggish segment to the top growth driver, reporting 11% core growth (14% reported). This acceleration is fueled by aggressive product innovation, specifically the launch of the new 9500 ICP-MS platform, which is capturing pent-up replacement demand in chemical and advanced materials markets.
Ignite Operating System Accelerating Margins
Agilent's enterprise operating framework, 'Ignite', continues to deliver. Non-GAAP operating margin expanded 130 bps YoY to 26.4%, and 180 bps sequentially. This proves that efficiency gains and procurement savings established in FY25 are structural and flow directly to the bottom line.
Life Sciences (LDG) Rebounding Strongly
Following a weak 3% core growth in Q1 (impacted by weather and Academic/Government softness), LDG growth is Accelerating, posting 9% core growth in Q2. Biopharma capital budgets are definitively unlocking, driving instrument placements.
CrossLab (ACG) Decelerating Sharply
A major red flag directly contradicting the 'broad-based strength' narrative: the ACG segment's core growth collapsed to 2% (from 6% in Q1). Because ACG represents higher-margin recurring revenue (services and consumables), a sustained deceleration here will heavily pressure future gross margins.
Cash Flow Reversing Opposite to Net Income
For the first six months of FY26, GAAP Net Income rose 21% YoY to $644M. Yet, Operating Cash Flow fell 16% to $545M. This massive divergence is primarily driven by an $85M increase in inventory and negative working capital dynamics. This suggests earnings quality is temporarily low and warrants strict monitoring.
Macro: Currency Masking Underlying Realities
While Agilent reported an impressive 10.0% top-line growth, a full 4 percentage points ($61M in Q2) of this was a pure foreign exchange tailwind. The underlying core growth of 6.3% is strong, but investors must discount the headline double-digit reported number as a macro artifact.
Other KPIs
Decelerating. Down from $441 million in the comparable 6-month period of FY25. Driven by weaker operating cash flow generation against $169 million in CapEx. This drop restricts capital flexibility for aggressive M&A or outsized buybacks.
Stable pacing compared to FY25. The company remains disciplined, returning capital to offset dilution while maintaining a strong balance sheet (over $1.8B in cash and equivalents).
Guidance
Accelerating slightly. The midpoint was raised by $40M. The new guide implies 4.5% to 6.0% core growth for the year. Given H1 performance, this suggests management is highly confident that the instrument replacement cycle has durable momentum into the back half of the year.
Accelerating. The midpoint was raised by 8 cents from the prior guide. This reflects absolute confidence in the Ignite OS to continue delivering margin expansion even as tariff and inflation pressures linger.
Decelerating. Implies 4.4% to 5.9% core growth, which is a step down from the 6.3% core growth achieved in Q2. Management is leaving room for macro turbulence or potential delays in budget deployment.
Stable. Flat sequentially compared to Q2's $1.49, implying operating margins will hold the substantial gains achieved this quarter rather than expanding further in Q3.
Key Questions
CrossLab Growth Deceleration
ACG core growth slowed dramatically to 2%. Is this due to a temporary destocking of consumables, lost service contracts, or a structural shift in how customers are utilizing existing fleets?
Working Capital and Cash Flow
Operating cash flow fell significantly year-over-year despite higher net income, heavily impacted by an $85M inventory drain. Are you intentionally building inventory to front-run supply chain risks, or is this a symptom of finished goods not shipping?
Q4 Implied Ramp
With Q3 guidance implying a sequential deceleration in core growth, hitting the raised full-year target mathematically requires a steep acceleration in Q4. What specific product lines or regional end-of-year budget flushes give you the confidence to underwrite that Q4 ramp?